TX-MARY-KAY-INC
3.4.2024 20:13:34 CEST | Business Wire | Press release
Mary Kay Inc., a global leader in women’s empowerment and staunch advocate for sustainability, is once again at the forefront of global ocean conservation efforts. The beauty brand was proud to participate at the 11th Annual World Ocean Summit & Expo, held in Lisbon, Portugal, from March 11-13. As a bronze level sponsor for the second consecutive year, Mary Kay demonstrated its unwavering commitment to fostering a sustainable blue economy as a private sector representative and through its long-standing collaboration with The Nature Conservancy (TNC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403166440/en/
Sandra Silva, General Manager of Mary Kay in Portugal, shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss. (Photo: Mary Kay Inc.)
The Annual World Ocean Summit & Expo, organized by Economist Impact, convened over 200 expert speakers and a diverse international audience to engage in meaningful discussions, workshops, and "How to" sessions. These gatherings focused on actionable solutions to some of the most pressing oceanic challenges, underlining the importance of collaborative efforts across sectors.
Sandra Silva, General Manager of Mary Kay Portugal, took an active role in the panel discussion titled "Developing Blue Nature-based Projects." Silva shared insights on the crucial need for collaborative efforts in marine conservation and highlighted the impact of incorporating gender perspectives in initiatives tackling climate change challenges and biodiversity loss.
"Mary Kay's participation at this year's World Ocean Summit was not only about reinforcing our dedication to ocean conservation, but also about spotlighting the essential role of women in these efforts,” said Silva. “We believe that our collective actions today are pivotal for the preservation of marine ecosystems. All stakeholders left the summit with a clear vision on new synergies, a focus on actionable strategies, and soundproof solutions to enhance ocean stewardship.”
Dr. Lizzie Mcleod, Global Ocean Director for The Nature Conservancy, expressed gratitude for their long-term and impactful relationship with Mary Kay. "Our strong collaboration stands as a testament to the power of joining forces across the scientific community and the private sector to improve ocean health. Mary Kay’s support of marine conservation initiatives, including the Super Reefs project in Palau, is one example of our collective effort to ensure a healthy and resilient ocean."
Mary Kay has been working to elevate ocean health and coral reef awareness through its support of The Nature Conservancy for 37 years. Some of the most recent projects include the Super Reef restoration in the Asia Pacific region and other projects in Hawaii, Palau, the Marshall Islands, and Belize. These projects align with Mary Kay's mission to not only enrich lives but also to ensure the longevity and health of marine environments for future generations.
DID YOU KNOW?
- Mary Kay began supporting The Nature Conservancy (TNC) in 1987 and has now contributed to projects for more than three decades across 100 conservation projects around the globe.
- As part of its mission to conserve the Earth’s land and water, TNC aims to conserve 4 billion hectares of ocean by 2030—including coral reefs.
- Out of more than 1,500 articles published on coral reef sciences in OECD countries, 33% of authors were women.1
- 13-24% of senior positions in the EU’s marine sciences sector are occupied by women.1
- 90% of women in fisheries and aquaculture are more involved in less well-paid or unpaid work.1
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly Twitter).
About The Nature Conservancy
The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world’s toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters, and oceans at an unprecedented scale, providing food and water sustainably, and helping make cities more sustainable. Working in 76 countries and territories —37 by direct conservation impact and 39 through partners— we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403166440/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
